patent.fyi
Applications  /  US 2026/0355315
United States Patent Application Publication

US 2026/0355315 A1

Published
Nov 12, 2026
Filed
Sep 20, 2023
Earliest date on the face
Sep 20, 2022
Classification
A61K 40/24
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Costimulation on a bead

What ifWhat if a coated bead delivers costimulation during effector-cell culture?
Claim language“an antigen expressed on an antigen presenting cell”

Polymer beads carry immobilized antibodies to CD3 and CD28. The bead surface clusters both receptors on responsive T cells and supplies activation and costimulation during ex vivo culture.

1.1Physical confinement of cell pairs

What ifWhat if a microwell brings an antigen presenting cell and an effector cell together?
Claim language“specifically binds to an antigen on the immune effector cell”

A shallow microwell confines the two cells, and a monospecific CD40 agonist supplies the activation signal to the antigen presenting cell. Surface peptide–major histocompatibility complexes and native costimulatory ligands provide signals to the effector cell during contact.

1.2Recognition through native receptors

What ifWhat if effector cells recognize antigen through their endogenous T-cell receptors?
Claim language“a heterologous receptor”

The culture uses T cells with native receptors that recognize a selected peptide bound to a major histocompatibility complex. Peptide-loaded presenting cells stimulate those T cells, and the associated CD3 complex transmits the activation signal.

1.3Replacement with functional cells

What ifWhat if functional replacement cells supply the activity lost from the exhausted population?
Claim language“rescuing immune effector cell activity or reversing immune effector cell exhaustion”

A separate aliquot of target-reactive T cells is expanded and tested for target-cell killing. The functional aliquot supplies the cytotoxic activity when transferred into the assay or culture.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Veterinary tumor response assay

A veterinary oncology assay combines canine tumor organoids, dendritic cells, and tumor-reactive lymphocytes from the same animal. One binding arm recognizes canine CD40 on dendritic cells, and the other recognizes canine CD8 on the lymphocytes. Time-lapse imaging tracks lymphocyte contacts with organoids, and a fluorescent viability stain measures tumor cell killing in wells with and without the bispecific polypeptide.

Component substitution

Single domain binding arm substitution

A single-domain antibody fragment that recognizes CD40 replaces the antigen-presenting-cell binding arm. A flexible glycine-serine linker joins this fragment to a single-chain variable fragment that recognizes an extracellular epitope tag on the effector cell. Both fragments form one soluble polypeptide, and dual binding is assessed by measuring effector cell and antigen-presenting cell conjugates by flow cytometry.

Fc free single chain scaffold

Two single-chain variable fragments replace the paired arms and constant-region scaffold of an antibody-format bispecific. A flexible peptide linker joins an antigen-presenting-cell-specific fragment to an effector-cell-specific fragment in a single soluble chain. The two fragments bind their respective cell-surface antigens, and fluorescence microscopy measures cell conjugate formation against a control chain with one binding fragment inactivated.

Parameter or scale variation

Timed exposure in microwell cocultures

A 96-well plate holds 100 microliters per well, with 10,000 effector cells and 5,000 antigen-presenting cells in each well. Replicate wells receive the same bispecific polypeptide concentration for 1, 4, or 24 hours. At the end of each exposure, the cells are washed, exposed to antigen-bearing tumor target cells, and assayed for target cell killing after a fixed 6-hour interval.

Combination with existing systems

Perfused tumor organoid coculture

A microfluidic perfusion chip contains a collagen gel chamber with tumor organoids, antigen-presenting cells, and effector cells. An adjacent fluid channel delivers the soluble bispecific polypeptide, which diffuses into the chamber and binds surface antigens on the two immune cell populations. Optical imaging tracks immune cell contacts and organoid viability, and timed outlet samples provide soluble cytokine measurements.

Automated or data-driven variant

Image guided bispecific exposure selection

A liquid handler dispenses antigen-presenting cells, effector cells, and serial dilutions of the bispecific polypeptide into a multiwell plate. An automated microscope images the two cell populations using distinct fluorescent labels, and image analysis measures the fraction of effector cells in contact with antigen-presenting cells. Software selects the lowest tested concentration that meets a preset contact threshold and transfers cells from replicate wells at that concentration to a separate tumor target killing assay.

Specific version of a part

CD40 and peptide tag binding

A single polypeptide contains two antibody variable-domain fragments joined by a flexible peptide linker. One fragment binds CD40 on a dendritic cell, and the other binds an exposed peptide tag on the effector-cell receptor.

Tagged receptor with costimulation

The receptor contains an extracellular antibody fragment for target recognition and an exposed peptide tag for bispecific binding. A transmembrane segment anchors the receptor, and intracellular CD28 and CD3 zeta domains transmit activation signals.

Recovery measured by target killing

Exposed effector cells are washed and challenged with fluorescently labeled antigen-bearing targets at a fixed effector-to-target ratio. Loss of viable targets relative to a matched untreated exhausted-cell culture measures recovery of cytotoxic activity.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2017/0333480 A1
Published
Nov 23, 2017
Filed
Nov 5, 2015
Class
A61K 35/17
Document BUS 2022/0072041 A1
Published
Mar 10, 2022
Filed
Jul 9, 2021
Class
A61K 35/17
Claim 1
Document A
Document B
1.1wherein the bispecific polypeptide comprises a first antigen binding protein that specifically binds to an antigen expressed on an antigen presenting cell (APC), preferably a professional APC, and a second binding antigen binding protein that specifically binds to an antigen on the immune effector cell,
In further aspects, the immune effector cells of the cell culture (comprising an engineered APC of the embodiments) express a chimeric T-cell receptor (CAR) that binds to an epitope of the target antigen in complex with the HLA expressed in the engineered APCs. The CAR may comprise antibody variable domains that bind to an epitope of the target antigen in complex with the HLA expressed in the APCs.
A · US 2017/0333480 A1 · ¶ 33
In further aspects, the immune effector cells of the cell culture (comprising an engineered APC of the embodiments) express a chimeric T-cell receptor (CAR) that binds to an epitope of the target antigen in complex with the HLA expressed in the engineered APCs. The CAR may comprise antibody variable domains that bind to an epitope of the target antigen in complex with the HLA expressed in the APCs.
B · US 2022/0072041 A1 · ¶ 34
1.2optionally wherein the immune effector cell expresses a heterologous receptor comprising an antigen binding protein and a signalling protein,
In some embodiments, the chimeric antigen receptor comprises: a) an intracellular signaling domain, b) a transmembrane domain, and c) an extracellular domain comprising an antigen binding domain.
A · US 2017/0333480 A1 · ¶ 116
In some embodiments, the chimeric antigen receptor comprises: a) an intracellular signaling domain, b) a transmembrane domain, and c) an extracellular domain comprising an antigen binding domain.
B · US 2022/0072041 A1 · ¶ 117
1.3thereby rescuing immune effector cell activity or reversing immune effector cell exhaustion.
The intracellular signaling domain of the chimeric antigen receptor of the embodiments is responsible for activation of at least one of the normal effector functions of the immune cell engineered to express a chimeric antigen receptor.
A · US 2017/0333480 A1 · ¶ 132
The intracellular signaling domain of the chimeric antigen receptor of the embodiments is responsible for activation of at least one of the normal effector functions of the immune cell engineered to express a chimeric antigen receptor.
B · US 2022/0072041 A1 · ¶ 133

An empty cell means only that no passage was reproduced there.

Statements in these documents
Such genetic engineering of T cells can be used to redirect the specificity of the cells and to provide therapeutic compositions having antigen-targeted cytotoxic activity.
A · US 2017/0333480 A1 · ¶ 4
There remains a need however, for improved T-cell and CAR constructs that allow for control of in vivo persistence.
A · US 2017/0333480 A1 · ¶ 4
Such genetic engineering of T cells can be used to redirect the specificity of the cells and to provide therapeutic compositions having antigen-targeted cytotoxic activity.
B · US 2022/0072041 A1 · ¶ 5
There remains a need however, for improved T-cell and CAR constructs that allow for control of in vivo persistence.
B · US 2022/0072041 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355315 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355315/, SHA-256 f24dbab8487432a40ae7f44391587bd2a073606f16c4b01935f548eed3bba76d
First published
Permanent addresshttps://patent.fyi/US20260355315/
Content fingerprint (SHA-256)f24dbab8487432a40ae7f44391587bd2a073606f16c4b01935f548eed3bba76d
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi